Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

By P. Kantoff, T. Schuetz, Brent A. Blumenstein, L. Glode, D. Bilhartz, M. Wyand, K. Manson, D. Panicali, R. Laus, J. Schlom and 4 more. Journal of Clinical Oncology, 2010

948 citations recorded by the source corpus.

Subfields: Immunology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bfb8a849f51eb4eaaa4de7b6834228fcfd9eff31

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Pulmonary and Respiratory Medicine

Citations in the corpus

The genomic complexity of primary human prostate cancer (2011, neutral): “This result is intriguing given the clinical benefit associated with immunotherapy for prostate cancer 26 , 27 .”
Dendritic-cell-based therapeutic cancer vaccines. (2013, background): “In a randomized phase II trial with a poxvirus-based vaccine expressing prostate-specific antigen (PSA) (PROSTVAC) and TRICOM (CD54, CD58, and CD80), men with metastatic prostate cancer showed an improved overall survival (8.5 months) (Kantoff et al., 2010b).”
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, background): “In 2010, a phase 3 trial of sipuleucel-T showed a survival benefit in 512 asymptomatic or minimally symptomatic mCRPC patients [77].”
Immune parameters affecting the efficacy of chemotherapeutic regimens (2011, background): “In 2010, the first patient-specific immunotherapy (sipuleucel-T) for advanced cancer—a dendritic cell-based vaccine against prostatic acid phosphatase—was approved by the FDA for the treatment of androgen-independent prostate cancer”
Therapeutic cancer vaccines. (2010, background): “5 months in the vaccinated group versus a control group of patients with hormone-resistant prostate cancer (21).”
Cancer immunotherapy comes of age (2011, neutral): “6 months in the control group (patients treated with empty vector plus saline”
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011, background): “On the basis of preliminary data, the study investigators hypothesize that patients with more indolent mCRPC (Halabi predicted survival 18 months) may best benefit from PSA-specific vaccine therapy (24).”